Recombinant Anti-LAG-3 antibody [EPR4392(2)] - C-terminal (ab180187)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR4392(2)] to LAG-3 - C-terminal
- Suitable for: IHC-P
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-LAG-3 antibody [EPR4392(2)] - C-terminal
See all LAG-3 primary antibodies -
Description
Rabbit monoclonal [EPR4392(2)] to LAG-3 - C-terminal -
Host species
Rabbit -
Tested applications
Suitable for: IHC-Pmore details
Unsuitable for: ICC/IF,IP or WB -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide within Human LAG-3 aa 450 to the C-terminus (Cysteine residue). The exact sequence is proprietary.
Database link: P18627 -
Positive control
- Human Hodgkins lymphoma and Human tonsil tissues
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.5% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR4392(2) -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab180187 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IHC-P | (2) |
1/1000. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
|
Notes |
---|
IHC-P
1/1000. Perform heat mediated antigen retrieval before commencing with IHC staining protocol. |
Target
-
Function
Involved in lymphocyte activation. Binds to HLA class-II antigens. -
Tissue specificity
On cell surface of activated NK and T-lymphocytes. -
Sequence similarities
Contains 3 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 Ig-like V-type (immunoglobulin-like) domain. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 3902 Human
- Omim: 153337 Human
- SwissProt: P18627 Human
- Unigene: 409523 Human
-
Alternative names
- CD223 antibody
- CD223 antigen antibody
- FDC protein antibody
see all
Images
-
Immunohistochemical analysis of paraffin embedded Human tonsil tissue labeling LAG-3 with ab180187 at 1/1000.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
-
Immunohistochemical analysis of paraffin embedded Human Hodgkins lymphoma tissue labeling LAG-3 with ab180187 at 1/1000.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
Datasheets and documents
-
SDS download
-
Datasheet download
References (12)
ab180187 has been referenced in 12 publications.
- Luo F et al. Correction to: Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes. Cancer Cell Int 22:46 (2022). PubMed: 35093085
- Machiraju D et al. Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients. Oncoimmunology 10:1926762 (2021). ELISA, IHC-P ; Human . PubMed: 34104542
- Cen S et al. BRAF Mutation as a Potential Therapeutic Target for Checkpoint Inhibitors: A Comprehensive Analysis of Immune Microenvironment in BRAF Mutated Colon Cancer. Front Cell Dev Biol 9:705060 (2021). PubMed: 34381786
- Peng QQ et al. Assessment of the expression and response of PD-1, LAG-3, and TIM-3 after neoadjuvant radiotherapy in rectal cancer. Neoplasma 68:742-750 (2021). PubMed: 33847134
- Sorrentino C et al. Colorectal Cancer-Associated Immune Exhaustion Involves T and B Lymphocytes and Conventional NK Cells and Correlates With a Shorter Overall Survival. Front Immunol 12:778329 (2021). PubMed: 34975867